Further to this, cabergoline, (a dopamine receptor agonist used for the treatment of hyperprolactinemia), was shown to reduce the size of endometriosis lesions via the inhibition of VEGFR2 in a mouse model of endometriosis [64,65]. Here, KDR is linked to hyperprolactinemia.